These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38725854)

  • 1. Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis.
    Wang M; Yuan C; Wu Z; Xu M; Chen Z; Yao J; Que Z; Tian J; Leung EL; Wang Z
    Int J Biol Sci; 2024; 20(7):2454-2475. PubMed ID: 38725854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Fibrillin-1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.
    Wang Z; Chen W; Zuo L; Xu M; Wu Y; Huang J; Zhang X; Li Y; Wang J; Chen J; Wang H; Sun H
    Cancer Commun (Lond); 2022 Mar; 42(3):245-265. PubMed ID: 35234370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
    Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
    Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration.
    Xiao X; Yang M; Xiao J; Zou J; Huang Q; Yang K; Zhang B; Yang F; Liu S; Wang H; Bai P
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):807-18. PubMed ID: 24638862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF-κB signaling.
    Yang M; Zou J; Zhu H; Liu S; Wang H; Bai P; Xiao X
    Oncol Rep; 2015 May; 33(5):2190-8. PubMed ID: 25760800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
    Hinchcliff E; Chelariu-Raicu A; Westin SN
    Curr Opin Obstet Gynecol; 2021 Feb; 33(1):19-25. PubMed ID: 33315700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    Tao M; Wu X
    J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    Miller RE; El-Shakankery KH; Lee JY
    J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    Cheng A; Rao Q; Liu Y; Huang C; Li J; Huo C; Lin Z; Lu H
    Gynecol Oncol; 2022 Dec; 167(3):502-512. PubMed ID: 36270832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
    Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
    Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
    Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
    Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z
    Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer.
    Ma H; Qi G; Han F; Peng J; Yuan C; Kong B
    Exp Mol Med; 2022 Jul; 54(7):999-1010. PubMed ID: 35859118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer.
    McMellen A; Yamamoto TM; Qamar L; Sanders BE; Nguyen LL; Ortiz Chavez D; Bapat J; Berning A; Post MD; Johnson J; Behbakht K; Nurmemmedov E; Chuong EB; Bitler BG
    Mol Cancer Res; 2023 Jan; 21(1):3-13. PubMed ID: 36149636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer.
    Zhan Z; Zhang J; Liang H; Wang C; Hong L; Liu W
    Adv Sci (Weinh); 2024 Sep; 11(34):e2400140. PubMed ID: 38973255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.